| scholarly article | Q13442814 |
| P2093 | author name string | Mohammed Kashani-Sabet | |
| Alex McMillan | |||
| Herschel S. Zackheim | |||
| P2860 | cites work | OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES. | Q34257888 |
| Trimetrexate in relapsed T-cell lymphoma with skin involvement. | Q40580546 | ||
| Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients | Q40970585 | ||
| Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients | Q41612139 | ||
| Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up | Q42480934 | ||
| Management of oral mucositis associated with cancer chemotherapy | Q43919656 | ||
| Topical corticosteroids for mycosis fungoides. Experience in 79 patients | Q44362773 | ||
| Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. | Q46402464 | ||
| The pharmacology of methotrexate | Q68011189 | ||
| Mycosis fungoides: management with topical nitrogen mustard | Q69449439 | ||
| Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology | Q72296676 | ||
| Short-term methotrexate therapy in psoriasis: a study of 197 patients | Q74471594 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dermatology | Q171171 |
| methotrexate | Q422232 | ||
| mycosis fungoides | Q1891209 | ||
| P304 | page(s) | 873-878 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients | |
| P478 | volume | 49 |
| Q47389863 | An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma |
| Q92652614 | Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL |
| Q36255777 | Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate |
| Q39363280 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial |
| Q40590985 | British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. |
| Q94340486 | Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma |
| Q48296904 | Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. |
| Q38655572 | Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy |
| Q37398969 | Cutaneous T-cell lymphoma in sub-Saharan Africa |
| Q37944565 | Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management |
| Q27024076 | Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management |
| Q36470196 | Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management |
| Q48034709 | Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. |
| Q36150634 | Emerging drugs in cutaneous T-cell lymphomas |
| Q40026998 | Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma |
| Q38212880 | Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review |
| Q37717711 | Management Strategies for Mycosis Fungoides in India |
| Q64069308 | Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel |
| Q36934406 | Menus for managing patients with cutaneous T-cell lymphoma |
| Q28083080 | Methotrexate and Pralatrexate |
| Q37052855 | Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides |
| Q35763375 | Mouth-rinses for the prevention of chemotherapy induced oral mucositis in children: a systematic review |
| Q93374418 | Mycosis Fungoides and Sézary Syndrome: An Update |
| Q30252152 | Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers |
| Q42665053 | Mycosis fungoides: therapeutic difficulties |
| Q38216976 | New and established treatment options for mycosis fungoides and Sézary syndrome - an update |
| Q37838501 | Oral complications in the treatment of cancer patients |
| Q26774768 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas |
| Q26772207 | Primary cutaneous lymphomas: diagnosis and treatment |
| Q88153215 | Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome |
| Q30239965 | Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? |
| Q30244553 | T-cell lymphomas, a challenging disease: types, treatments, and future. |
| Q33746059 | The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications |
| Q37981730 | The use of methotrexate in dermatology: a review |
| Q34574172 | Treatment of mycosis fungoides: overview |
Search more.